Tempus AI (NASDAQ:TEM) CEO Sells $597,148.50 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 13,550 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $597,148.50. Following the completion of the sale, the chief executive officer directly owned 603,558 shares of the company’s stock, valued at approximately $26,598,801.06. The trade was a 2.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Up 1.3%

Shares of NASDAQ TEM traded up $0.61 during trading hours on Thursday, hitting $46.49. The company had a trading volume of 3,802,434 shares, compared to its average volume of 5,629,236. The stock has a market capitalization of $8.35 billion, a P/E ratio of -27.03 and a beta of 3.99. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The firm’s 50 day moving average is $49.11 and its 200-day moving average is $59.69.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.24) EPS. On average, analysts expect that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Tempus AI by 8.7% during the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after acquiring an additional 817,014 shares during the last quarter. ARK Investment Management LLC lifted its position in Tempus AI by 5.3% during the fourth quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares during the last quarter. GC Wealth Management RIA LLC acquired a new stake in Tempus AI during the fourth quarter worth approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. grew its holdings in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TEM. TD Cowen boosted their price objective on shares of Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. HC Wainwright cut their price objective on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Jefferies Financial Group initiated coverage on Tempus AI in a research report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective for the company. Finally, Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research report on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.